Itraconazole Capsule (Itraconazole)

Adult dosage

To increase absorption, it is preferable to administer this medicine immediately after a meal. The capsules must be swallowed whole. 1. Short-term treatment 1) Vulvovaginal candidiasis: Administer itraconazole 200 mg twice daily (morning and evening) for 1 day, or 200 mg once daily for 3 days. 2) Pityriasis versicolor: Administer 200 mg once daily for 7 days. 3) Tinea corporis and tinea cruris: Administer 100 mg once daily for 15 days. 4) Tinea manuum (interdigital type) and tinea pedis (interdigital type): Administer 100 mg once daily for 15 days. 5) Tinea manuum (palms) and tinea pedis (soles): Administer 100 mg once daily for 30 days or 200 mg twice daily for 7 days. 6) Oral candidiasis: Administer 100 mg once daily for 15 days. 7) Fungal keratitis: Administer 200 mg once daily for 21 days. 2. Onychomycosis 1) Pulse therapy Administer 200 mg twice daily for 1 week, followed by a 3-week treatment-free period; this constitutes one cycle. Administer up to 2 cycles if only the fingernails are infected and up to 3 cycles if the toenails are infected. Site of onychomycosis Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9 Toenails (with or without fingernail infection) Treatment Treatment-free Treatment Treatment-free Treatment Fingernails Treatment Treatment-free Treatment 2) Continuous therapy Administer 200 mg once daily for 3 months. 3. Systemic fungal infections In patients with impaired immune function, such as those with neutropenia, AIDS, or organ transplant recipients, the oral bioavailability of this medicine may be reduced; therefore, if necessary, the dose may be doubled. Aspergillosis: 200mg once daily for 2~5 months. For invasive or disseminated disease, increase to 200mg twice daily. Candidiasis: 100~200mg once daily for 3 weeks~7 months. Cryptococcal meningitis: 200mg twice daily for 2 months~1 year. Maintenance therapy (for AIDS patients only): 200mg once daily. Paracoccidioidomycosis: 100mg once daily for 6 months. There are no efficacy data for this dosage regimen for the treatment of paracoccidioidomycosis in ADIS patients. 1 The duration of treatment should be adjusted according to clinical response. 2 The duration of treatment should depend on immune recovery.

This drug is not recommended for patients with decreased heart function, particularly those with congestive heart failure. If symptoms of heart failure occur, administration should be discontinued immediately. It should not be taken by individuals with a history of allergy to this medication or those who have had hypersensitivity reactions to its components. Additionally, taking this drug with certain medications may result in severe side effects, so it is essential to check the list of contraindicated medications. Women who are pregnant or may become pregnant, as well as those who are nursing, should avoid using this medication. Patients with impaired liver or kidney function should use this medication with caution, and dosage adjustments may be necessary. During treatment, regular liver function tests should be conducted to monitor for potential liver toxicity. Patients with weakened immune systems should closely monitor the drug's effectiveness and side effects, and dosage adjustments may be needed. This drug has many interactions with various medications, so individuals taking other drugs should consult a healthcare professional. Dizziness, visual and auditory disturbances may occur; caution is needed when driving or operating machinery. There is no specific antidote for overdose, and symptomatic treatment should be administered, as it is not removed by dialysis. Keep out of reach of children and store in the original container to prevent misuse or degradation of quality.

Decreased myocardial contractility, heart failure, headache, nausea, abdominal pain, rhinitis, sinusitis, upper respiratory tract infection, leukopenia, hypersensitivity, taste disturbance, sensory impairment, sensation abnormalities, tinnitus, constipation, diarrhea, indigestion, abdominal distension, vomiting, liver dysfunction, hyperbilirubinemia, itching, rash, urticaria, polyuria, erectile dysfunction, menstrual disorders, edema, granulocyte deficiency, thrombocytopenia, anaphylactic-like reactions, hyperglycemia, hyperkalemia, hypokalemia, hypomagnesemia, confusion, peripheral neuropathy, dizziness, drowsiness, tremor, heart failure, left ventricular failure, tachycardia, hypertension, hypotension, pulmonary edema, speech disorders, cough, gastrointestinal disorders, liver failure, hepatitis, jaundice, erythematous rash, hyperhidrosis, myalgia, arthralgia, renal disorders, urinary incontinence, systemic edema, facial edema, chest pain, fever, pain, fatigue, chills, elevated alanine aminotransferase, elevated aspartate aminotransferase, increased serum alkaline phosphatase, increased serum lactate dehydrogenase, elevated blood urea, increased gamma-glutamyl transferase, increased liver enzymes, abnormal urinalysis, leukocytosis, eosinophilia, anemia, vascular edema, serum sickness, angioedema, anaphylaxis, anaphylactic shock, allergic reaction, diplopia, visual impairment, hearing loss, ventricular ectopy, atrial block, palpitations, increased bowel motility, belching, glossitis, stomatitis, abdominal lumbar pain, pancreatitis, elevated serum total protein, elevated total bilirubin, increased LAP, loss of appetite, fatigue, brown urine, skin and mucous membrane syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis, Rielle syndrome, erythema multiforme, hair loss, photosensitivity reaction, exfoliative dermatitis, leukocytoclastic vasculitis, acute generalized exanthematous pustulosis, elevated BUN, positive urine protein reaction, positive urine glucose reaction, decreased libido, drowsiness, shoulder stiffness, insomnia, chest pain, elevated serum triglycerides, burning sensation, elevated serum uric acid, elevated serum potassium, serum sickness, angioedema, anaphylactic reaction, hypertriglyceridemia, tremor, visual impairment, temporary hearing loss, permanent hearing loss, congestive heart failure, dyspnea, significant hepatotoxicity, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, increased serum creatine phosphokinase

This medication should be stored in a well-sealed container that is airtight, at room temperature between 1 and 30 degrees Celsius. This storage method will help maintain the effectiveness of the drug and prevent degradation.

Appearance

A hard capsule with a blue upper part and a pink lower part filled with white or grayish spherical pellets.

Package unit

30 capsules/bottle, 100 capsules/bottle